tbuckley/cabot-search huggingface dataset:
Management of adults and children receiving CAR T-cell therapy: 2021 best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE) and the European Haematology Association (EHA)
Authors: P.J. Hayden, C. Roddie, P. Bader, G.W. Basak, H. Bonig, C. Bonini, C. Chabannon, F. Ciceri, S. Corbacioglu, R. Ellard, F. Sanchez-Guijo, U. Jäger, M. Hildebrandt, M. Hudecek, M.J. Kersten, U. Köhl, J. Kuball, S. Mielke, M. Mohty, J. Murray, A. Nagler, J. Rees, C. Rioufol, R. Saccardi, J.A. Snowden, J. Styczynski, M. Subklewe, C. Thieblemont, M. Topp, Á.U. Ispizua, D. Chen, R. Vrhovac, J.G. Gribben, N. Kröger, H. Einsele, I. Yakoub-Agha
Journal: Annals of Oncology (2021)

Several commercial and academic autologous chimeric antigen receptor T-cell (CAR-T) products targeting CD19 have been approved in Europe for relapsed/refractory B-cell acute lymphoblastic leukemia, high-grade B-cell lymphoma and mantle cell lymphoma. Products for other diseases such as multiple myeloma and follicular lymphoma are likely to be approved by the European Medicines Agency in the near future.The European Society for Blood and Marrow Transplantation (EBMT)-Joint Accreditation Committee of ISCT and EBMT (JACIE) and the European Haematology Association collaborated to draft best practice recommendations based on the current literature to support health care professionals in delivering consistent, high-quality care in this rapidly moving field.Thirty-six CAR-T experts (medical, nursing, pharmacy/laboratory) assembled to draft recommendations to cover all aspects of CAR-T patient care and supply chain management, from patient selection to long-term follow-up, post-authorisation safety surveillance and regulatory issues.We provide practical, clinically relevant recommendations on the use of these high-cost, logistically complex therapies for haematologists/oncologists, nurses and other stakeholders including pharmacists and health sector administrators involved in the delivery of CAR-T in the clinic.
Errors in Key Points, Abstract, Results, and Figures
Authors: Pierre-Marie Roy, Thomas Moumneh, Andrea Penaloza
Journal: JAMA Cardiology (2021)

Omar F. AbouEzzeddine, MDCM, MS; Daniel R. Davies, MD; Christopher G. Scott, MS; Ahmed U. Fayyaz, MD; J. Wells Askew, MD; Paul M. McKie, MD; Peter A. Noseworthy, MD; Geoffrey B. Johnson, MD, PhD; Shannon M. Dunlay, MD, MS; Barry A. Borlaug, MD; Panithaya Chareonthaitawee, MD; Veronique L. Roger, MD, MPH; Angela Dispenzieri, MD; Martha Grogan, MD; Margaret M. Redfield, MD
Self-reported Behaviors Regarding Medications to Save Money Among Sexual Minority Adults in the US, 2015-2018
Authors: Rishub K. Das, Gilbert Gonzales
Journal: JAMA (2021)

This survey-based study of US adults from gender and sexual minority populations examines self-reported behaviors to save money on prescription medications, including skipping doses, purchasing from other countries, delaying refills, taking less medication, and using alternative therapies.
Revised clinical and molecular risk strata define the incidence and pattern of failure in medulloblastoma following risk-adapted radiotherapy and dose-intensive chemotherapy: results from a phase III multi-institutional study
Authors: John T Lucas, Christopher L Tinkle, Jie Huang, Arzu Onar-Thomas, Sudharsan Srinivasan, Parker Tumlin, Jared B Becksfort, Paul Klimo, Frederick A Boop, Giles W Robinson, Brent A Orr, Julie H Harreld, Matthew J Krasin, Paul A Northcott, David W Ellison, Amar Gajjar, Thomas E Merchant
Journal: Neuro-Oncology (2021)

We characterize the patterns of progression across medulloblastoma (MB) clinical risk and molecular subgroups from SJMB03, a Phase III clinical trial.One hundred and fifty-five pediatric patients with newly diagnosed MB were treated on a prospective, multi-center phase III trial of adjuvant radiotherapy (RT) and dose-intense chemotherapy with autologous stem cell transplant. Craniospinal radiotherapy to 23.4 Gy (average risk, AR) or 36-39.6 Gy (high risk, HR) was followed by conformal RT with a 1 cm clinical target volume to a cumulative dose of 55.8 Gy. Subgroup was determined using 450K DNA methylation. Progression was classified anatomically (primary site failure (PSF) +/- distant failure (DF), or isolated DF), and dosimetrically.Thirty-two patients have progressed (median follow-up 11.0 years (range, 0.3-16.5 y) for patients without progression). Anatomic failure pattern differed by clinical risk (P = .0054) and methylation subgroup (P = .0034). The 5-year cumulative incidence (CI) of PSF was 5.1% and 5.6% in AR and HR patients, respectively (P = .92), and did not differ across subgroups (P = .15). 5-year CI of DF was 7.1% vs. 28.1% for AR vs. HR (P = .0003); and 0% for WNT, 15.3% for SHH, 32.9% for G3, and 9.7% for G4 (P = .0024). Of 9 patients with PSF, 8 were within the primary site RT field and 4 represented SHH tumors.The low incidence of PSF following conformal primary site RT is comparable to prior studies using larger primary site or posterior fossa boost volumes. Distinct anatomic failure patterns across MB subgroups suggest subgroup-specific treatment strategies should be considered.
Randomized trial of two artificial intelligence coaching interventions to increase physical activity in cancer survivors
Authors: Ahmed Hassoon, Yasmin Baig, Daniel Q. Naiman, David D. Celentano, Dina Lansey, Vered Stearns, Josef Coresh, Jennifer Schrack, Seth S. Martin, Hsin-Chieh Yeh, Hadas Zeilberger, Lawrence J. Appel
Journal: npj Digital Medicine (2021)

Physical activity (PA) has numerous health benefits. Personalized coaching may increase adherence to PA recommendations, but it is challenging to deliver personalized coaching in a scalable manner. The objective of our study was to determine whether novel artificially intelligent (AI) coaching interventions increase PA among overweight or obese, physically inactive cancer survivors compared to a control arm that receives health information. We conducted a single-center, three-arm randomized trial with equal allocation to (1) voice-assisted AI coaching delivered by smart speaker (MyCoach), (2) autonomous AI coaching delivered by text message (SmartText), and (3) control. Data collection was automated via sensors and voice technology, effectively masking outcome ascertainment. The primary outcome was change in mean steps per day from baseline to the end of follow-up at 4 weeks. Of the 42 randomized participants, 91% were female, and 36% were Black; mean age was 62.1 years, and mean BMI was 32.9 kg/m2. The majority were breast cancer survivors (85.7%). At the end of 4 weeks follow-up, steps increased in the MyCoach arm by an average of 3618.2 steps/day; the net gain in this arm was significantly greater [net difference = 3568.9 steps/day (95% CI: 1483-5655), P value <0.001] compared to control arm, and [net difference = 2160.6 steps/day (95% CI: 11-4310), P value 0.049] compared to SmartText. In conclusion, AI-based voice-assisted coaching shows promise as a practical method of delivering scalable, individualized coaching to increase physical activity in sedentary cancer survivors. Additional research is needed to replicate these findings in a broader population of cancer survivors and to investigate the effects of these interventions in the general population.ClinicalTrials.gov Identifier: NCT03212079, July 11, 2017, https://clinicaltrials.gov/ct2/show/NCT03212079 .
Trastuzumab Emtansine Plus Pertuzumab Versus Taxane Plus Trastuzumab Plus Pertuzumab After Anthracycline for High-Risk Human Epidermal Growth Factor Receptor 2–Positive Early Breast Cancer: The Phase III KAITLIN Study
Authors: Ian E. Krop, Seock-Ah Im, Carlos Barrios, Hervé Bonnefoi, Julie Gralow, Masakazu Toi, Paul A. Ellis, Luca Gianni, Sandra M. Swain, Young-Hyuck Im, Michelino De Laurentiis, Zbigniew Nowecki, Chiun-Sheng Huang, Louis Fehrenbacher, Yoshinori Ito, Jigna Shah, Thomas Boulet, Haiying Liu, Harrison Macharia, Peter Trask, Chunyan Song, Eric P. Winer, Nadia Harbeck
Journal: Journal of Clinical Oncology (2021)

We aimed to improve efficacy and reduce toxicity of high-risk human epidermal growth factor receptor 2 (HER2)-positive early breast cancer (EBC) treatment by replacing taxanes and trastuzumab with trastuzumab emtansine (T-DM1).The phase III KAITLIN study (NCT01966471) included adults with excised HER2-positive EBC (node-positive or node-negative, hormone receptor-negative, and tumor > 2.0 cm). Postsurgery, patients were randomly assigned 1:1 to anthracycline-based chemotherapy (three-four cycles) and then 18 cycles of T-DM1 plus pertuzumab (AC-KP) or taxane (three-four cycles) plus trastuzumab plus pertuzumab (AC-THP). Adjuvant radiotherapy/endocrine therapy was permitted. Coprimary end points were invasive disease-free survival (IDFS) in the intention-to-treat node-positive and overall populations with hierarchical testing.The median follow-up was 57.1 months (interquartile range, 52.1-60.1 months) for AC-THP (n = 918) and 57.0 months (interquartile range, 52.1-59.8 months) for AC-KP (n = 928). There was no significant IDFS difference between arms in the node-positive (n = 1,658; stratified hazard ratio [HR], 0.97; 95% CI, 0.71 to 1.32) or overall population (n = 1846; stratified HR, 0.98; 95% CI, 0.72 to 1.32). In the overall population, the three-year IDFS was 94.2% (95% CI, 92.7 to 95.8) for AC-THP and 93.1% (95% CI, 91.4 to 94.7) for AC-KP. Treatment completion rates (ie, 18 cycles) were 88.4% for AC-THP and 65.0% for AC-KP (difference driven by T-DM1 discontinuation because of laboratory abnormalities [12.5%]). Similar rates of grade ≥ 3 (55.4% v 51.8%) and serious adverse events (23.3% v 21.4%) occurred with AC-THP and AC-KP, respectively. KP decreased clinically meaningful deterioration in global health status versus THP (stratified HR, 0.71; 95% CI, 0.62 to 0.80).The primary end point was not met. Both arms achieved favorable IDFS. Trastuzumab plus pertuzumab plus chemotherapy remains the standard of care for high-risk HER2-positive EBC.
92P PD-L1 inhibitors as monotherapy for the first-line treatment of non-small cell lung cancer in PD-L1 positive patients: A safety data network meta-analysis
Authors: M.R. García Campelo, E. Arriola Aperribay, B. Campos Balea, M. López-Brea, J. Fuentes Pradera, J. de Castro Carpeno, C. Aguado, D. Perez Parente, F. de Oro-Pulido, D. Rodriguez Abreu
Journal: Annals of Oncology (2021)
Average corticosteroid dose and risk for HBV reactivation and hepatitis flare in patients with resolved hepatitis B infection
Authors: Zhenyu Zhong, Weiting Liao, Lingyu Dai, Xiaojie Feng, Guannan Su, Yu Gao, Qiuying Wu, Peizeng Yang
Journal: Annals of the Rheumatic Diseases (2021)

Objectives Corticosteroids remain the mainstay of treatment for rheumatic diseases but can cause hepatitis B virus (HBV) reactivation in patients with resolved HBV infection. Risk assessment and stratification are needed to guide the management of these patients before corticosteroid therapy. Methods We prospectively enrolled patients with negative hepatitis B surface antigen positive Anti-hepatitis B core status with or without corticosteroid use and determined corticosteroid exposure by calculating cumulative dose and time-weighted average daily dose of prednisone. The primary outcome was the time to a composite of HBV reactivation, hepatitis flare or severe hepatitis. Results Among 1303 participants, the median of cumulative dose and time-weighted average dose of prednisone used in this cohort was 3000 mg (IQR: 300–6750 mg) and 15 mg/day (IQR: 10–20 mg/day), respectively. In multivariable analyses, cumulative dose showed inverted V-shaped relationship with primary events, which peaked at a cumulative dose of 1506 mg (HR: 3.72; 95% CI, 1.96 to 7.08). Quartiles of time-weighted average dose were independently associated with a monotonic increase in event risk (HR per quartile increase: 2.15; 95% CI, 1.56 to 2.98), reaching an HR of 49.48 (95% CI, 6.24 to 392.48) in the top quartile. The incidence of primary outcome was 16.67 per 100 person-years in the top quartile of time-weighted average dose (Q4&gt;20 mg/day). Other quartiles all had an incidence of primary outcome less than 10 per 100 person-years. Conclusion Patients with time-weighted average prednisone dose greater than 20 mg/day would be classified as the high risk for HBV reactivation or hepatitis flare. Prophylactic Anti-HBV therapy may be needed for these high-risk patients. Trial registration number ChiCTR1900023955.
Prevalence of High-risk Nonalcoholic Steatohepatitis (NASH) in the United States: Results From NHANES 2017–2018
Authors: Eduardo Vilar-Gomez, Raj Vuppalanchi, Andrea Mladenovic, Niharika Samala, Samer Gawrieh, Phil N. Newsome, Naga Chalasani
Journal: Clinical Gastroenterology and Hepatology (2021)
143P Novel anti-PD-L1 antibody TQB2450 (T) in combination with anlotinib (A) in patients with advanced soft tissue sarcoma (STS), the results from the expanded sample size and updated data
Authors: J. Liu, Z. Fan, W. Guo, T. Gao, S. Li, J. Xu, C. Bai, R. Xue, L. Zhang, L. Xie, Z. Tan
Journal: Annals of Oncology (2021)
Reply: Prednisolone plus itraconazole in acute-stage allergic bronchopulmonary aspergillosis complicating asthma: is the benefit worth the risk?
Authors: Ritesh Agarwal, Valliappan Muthu
Journal: European Respiratory Journal (2021)

We thank A. Havette and co-workers for the interest shown in our article [1]. They suggest that the benefit of itraconazole–prednisolone combination in allergic bronchopulmonary aspergillosis (ABPA) may be due to the increased bioavailability of inhaled corticosteroids (ICS) resulting from the CYP3A4 inhibition by itraconazole. While theoretically correct, there is no evidence that the interaction with ICS mediates the beneficial effect of itraconazole. Moreover, none of the previous trials of oral triazoles in ABPA have explored this aspect [2–5]. Our recent study suggests that itraconazole is likely beneficial when combined with prednisolone. Whether ICS potentiates this synergy remains to be seen. A. Havette and co-workers further indicate that discontinuing itraconazole and oral steroids at 4 months in the combination arm could have diminished the problem of ICS–itraconazole interaction. We, however, feel that the best study design to investigate the actual effect of prednisolone–itraconazole combination would be to use the combination in ABPA sans asthma, where ICS are not routinely used [6]. The benefits outweigh the risks of using combined prednisolone–itraconazole for treating ABPA complicating asthma <https://bit.ly/3oyX53I>
119TiP Dual-immunotherapy and short-course medium-dose radiotherapy, followed by surgery for tumor microenvironment modification in early stage NSCLC: The DIRECT-trial
Authors: C. Dickhoff, S. Senan, F.L. Schneiders, J. Veltman, S. Hashemi, M. Fransen, D. Heineman, T. Radonic, P. van de Ven, I.H. Bartelink, L. Meijboom, D. Oprea-Lager, J. Garcia-Vallejo, N. Bouwhuis, T.D. de Gruijl, I. Bahce
Journal: Annals of Oncology (2021)
Abstract 16935: A Rare Case Of COVID-19 Induced Thrombus-in-Transit Going Through A PFO In A Pregnant Patient
Authors: Yosef Manla, Yazan Aljabery, Haris Azeem, gopal bhatnagar, Laszlo Gobolos, Fahad Alsindi, Ahmed Bafadel
Journal: Circulation (2021)

Case Presentation: A 42-year-old female in her 24 th week of pregnancy was admitted to an outside hospital with respiratory failure due to COVID-19 pneumonia and was managed with Remdesivir, Dexamethasone, and pharmacological DVT prophylaxis. Her chest CT showed a massive PE. Due to instability, a cesarean section was necessitated, which resulted in delivering a stillborn baby. Two days later, she developed a severe circulatory shock with acute renal failure, not responding to conventional vasopressors/inotropic therapy. VA-ECMO was inserted for hemodynamic stabilization and the patient was transferred to our advanced ICU for further management. Upon arrival, the clinical picture was suggestive of COVID-19- induced thrombotic storm. Furthermore, the patient underwent several imaging studies which showed additional de-novo thromboembolic events in the brain (stroke), pulmonary circuit (PE), and portal circuit (hepatic thrombosis), which were managed medically. A transesophageal echocardiogram was done and revealed a large highly mobile echogenic structure, measuring up to 40 mm, crossing a patent foramen ovale (PFO) highly suggestive of thrombus in transit, in addition to the findings of significantly dilated RA and RV cavities (Figure 1 A, B). The team decided to perform an urgent surgical excision of that highly mobile thrombus accompanied by PFO closure to prevent catastrophic strokes. The thrombus in transit was extracted and was consistent with prior obtained imaging (Figure 1 C, D). Her postoperative course was uncomplicated. With advanced ICU and multidisciplinary care, she was finally discharged home hemodynamically stable on anticoagulation with Apixaban. Discussion: COVID-19 induced thrombus in-transit crossing a PFO is a rare finding and carries a high risk of paradoxical embolism. Multidisciplinary approach in integrating clinical and imaging findings can further help in a timely-manner decision making which improves patient's outcome.
Missed lesions and artificial intelligence during colonoscopy: the tireless working expert in the room
Authors: Timo Rath
Journal: Endoscopy (2021)

Although colonoscopy is generally considered to be the most accurate screening modality for detecting polyps, a substantial number of polyps are still missed. Recent data show a worrying proportion of missed lesions during screening or surveillance colonoscopy. In a meta-analysis of 43 publications and more than 15 000 tandem colonoscopies, miss rates of 26 % for adenomas, 9 % for advanced adenomas, and 27 % for serrated polyps were calculated [1]. Needless to say, missed lesions, especially missed advanced adenomas, may have the potential to develop into cancer, and it is thought that at least 50 % of all interval colorectal cancers arise from lesions missed during colonoscopy [2].
A Review of Chronic Pelvic Pain in Women
Authors: Amelia K. Mardon, Hayley B. Leake, K. Jane Chalmers
Journal: JAMA (2021)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2022 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
HDAC2 Facilitates Pancreatic Cancer Metastasis
Authors: Lukas Krauß, Bettina C. Urban, Sieglinde Hastreiter, Carolin Schneider, Patrick Wenzel, Zonera Hassan, Matthias Wirth, Katharina Lankes, Andrea Terrasi, Christine Klement, Filippo M. Cernilogar, Rupert Öllinger, Niklas de Andrade Krätzig, Thomas Engleitner, Roland M. Schmid, Katja Steiger, Roland Rad, Oliver H. Krämer, Maximilian Reichert, Gunnar Schotta, Dieter Saur, Günter Schneider
Journal: Cancer Research (2021)

The mortality of patients with pancreatic ductal adenocarcinoma (PDAC) is strongly associated with metastasis, a multistep process that is incompletely understood in this disease. Although genetic drivers of PDAC metastasis have not been defined, transcriptional and epigenetic rewiring can contribute to the metastatic process. The epigenetic eraser histone deacetylase 2 (HDAC2) has been connected to less differentiated PDAC, but the function of HDAC2 in PDAC has not been comprehensively evaluated. Using genetically defined models, we show that HDAC2 is a cellular fitness factor that controls cell cycle in vitro and metastasis in vivo, particularly in undifferentiated, mesenchymal PDAC cells. Unbiased expression profiling detected a core set of HDAC2-regulated genes. HDAC2 controlled expression of several prosurvival receptor tyrosine kinases connected to mesenchymal PDAC, including PDGFRα, PDGFRβ, and EGFR. The HDAC2-maintained program disabled the tumor-suppressive arm of the TGFβ pathway, explaining impaired metastasis formation of HDAC2-deficient PDAC. These data identify HDAC2 as a tractable player in the PDAC metastatic cascade. The complexity of the function of epigenetic regulators like HDAC2 implicates that an increased understanding of these proteins is needed for implementation of effective epigenetic therapies.
Comments on Study About US Female Surgeons—Reply
Authors: Erika L. Rangel, Sarah Rae Easter, Eugene Kim
Journal: JAMA Surgery (2021)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Surgery HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Surgery journal